Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEAL-1L niraparib plus pembrolizumab maintenance in advanced non-small cell lung cancer
NL-OMON54238Phase 3Recruiting
- Sponsor
- GSK
- Start
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Niraparib plus pembrolizumab with Placebo plus pembrolizumab (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Apr 2023; status: recruiting.
02
Drugs
niraparibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54238.